Aug 2026· Nature Communications· Vol 17· 0 citations· 33 references
Medicine
Abstract
Alanyl-tRNA synthetase 1 (AARS1) was recently identified as a lactyltransferase responsible for protein lactylation, a modification associated with epigenetic regulation and metabolic adaptation. Here, we report compound XY353, which covalently binds C184 of AARS1, inducing steric clashes with F175 and triggering structural rearrangements in the region that displace W176, a key residue for lactate binding. By means of a combination of a variety of biophysical and enzymatic assays with MD simulations and structural analysis, we show that XY353 and its derivative XY353-1 inhibit AARS1 by competing with lactate via the C184–F175–W176 relay, supporting a covalent allosteric mechanism of inhibition, which is further confirmed by our cellular data that XY353-1 reduces lactylation of the AARS1 substrate YAP and suppresses the proliferation of HGC-27 cells. Collectively, these findings identify a covalent allosteric mechanism for AARS1 inhibition and provide chemical tools to explore its biological functions. AARS1 is a recently identified protein lactyltransferase. Here, the authors report covalent inhibitors of AARS1, reveal a covalent-ligand-induced allosteric mechanism, and demonstrate suppression of protein lactylation in cells.
A structure dynamics-based design strategy is reported that transforms OB into a selective antibacterial agent through rational modification of the nitrophenyl moiety, and establishes a 'kinetic sensor' strategy for achieving species selectivity.
These findings establish the structural basis of sulX-mediated sulfonamide degradation and provide a foundation for understanding sulfonamide resistance mechanisms.
Yu-Mei Hu, Wan-Huan Liu, Qi-Shan Zhang et al.· Journal of Hazardous Materia...· 0 citations
Adenosine-to-inosine (A-to-I) RNA editing by ADAR1 is a key post-transcriptional modification, and mutations in ADAR1 lead to Aicardi-Goutières syndrome (AGS), an autoimmune disorder. Despite its biological and clinical relevance, the regulation of ADAR1 activity remains incompletely understood. Using a combination of...
Francisco Antonio Venegas Solis, Mengsi Lu, Roni Cohen-Fultheim et al.· RNA: A publication of the RN...· 0 citations
Repurposing the clinical-stage Bcl-xL BH3 mimetic A-1331852 is identified as a potent PTP1B inhibitor demonstrating a selectivity margin of at least 50-fold over TCPTP, highlighting A-1331852 as a promising starting point for developing PTP1B inhibitors designed to exploit transient, substrate-induced binding states.
Nathaly Vasquez-Martínez, Alejandro Sosa-Peinado, Francisco Cortés-Benítez et al.· Bioorganic & Medicinal Chemi...· 0 citations
Cytochrome P450s catalyze an array of reactions including crosslinking of aromatic side chains in the biosynthesis of ribosomally synthesized and post-translationally modified peptides (RiPPs). ApyO is a cytochrome P450 that forms a C─C bond between two tyrosines in a YLY motif in the substrate ApyA, the precursor pept...
Chandrashekhar Padhi, Dinh T. Nguyen, Ling-Yang Zhu et al.· Angewandte Chemie· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.